SCHEMBL2368979

SCHEMBL2368979

Cc1ccc(-c2csc3ncnc(N(C)c4ccco4)c23)nc1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 0.36
MAPK1 P28482 2/20 0.36
TSHR P16473 1/20 0.36
MAPT P10636 4/20 0.36
ALDH1A1 P00352 4/20 0.36
HPGD P15428 2/20 0.36
L3MBTL1 Q9Y468 2/20 0.36
POLB P06746 1/20 0.36
ALOX15 P16050 1/20 0.36
HSD17B10 Q99714 1/20 0.36
KMT2A Q03164 4/20 0.35
PKM P14618 1/20 0.35
HTT P42858 4/20 0.33
MEN1 O00255 2/20 0.33
KDM4E B2RXH2 1/20 0.33
PIP4K2C Q8TBX8 1/20 0.32
GAA P10253 1/20 0.32
FGFR1 P11362 2/20 0.31
CCR1 P32246 1/20 0.31
CCR5 P51681 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2369096 0.86 ALDH1A1 (0.47) LMNAMAPK1TSHRMAPTALDH1A1
SCHEMBL2368309 0.81 LMNA (0.55) LMNAMAPK1TSHRALDH1A1HPGD
SCHEMBL3382534 0.79 HTT (0.48) LMNAMAPK1TSHRMAPTALDH1A1
SCHEMBL3386933 0.77 MAPT (0.55) LMNAMAPK1MAPTALDH1A1HPGD
SCHEMBL2368978 0.73 SMN1; SMN2 (0.56) LMNAMAPK1TSHRMAPTALDH1A1
SCHEMBL6641938 0.71 CCR1 (0.42) LMNATSHRMAPTALDH1A1L3MBTL1
SCHEMBL2368364 0.71 MAPT (0.55) LMNATSHRMAPTALDH1A1HPGD
SCHEMBL379641 0.69 KDR (0.43) MAPTALDH1A1HPGDL3MBTL1POLB
SCHEMBL3385305 0.68 FGFR1 (0.35) LMNAMAPK1TSHRALDH1A1L3MBTL1
SCHEMBL3388145 0.67 ALDH1A1 (0.45) LMNAMAPK1TSHRMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8022076-B2 Thieno[2,3-d]pyrimidine derivatives as potassium channel modulators; antiarrhythmia agents XENTION LIMITED (GB) 2011-09-20 US disclosed
EP-1641803-B3 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS XENTION LTD (GB) 2010-12-08 EP disclosed
EP-1641803-B1 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS XENTION LTD (GB) 2009-03-18 EP disclosed
EP-1641803-A1 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS Xention Discovery Limited (GB) 2006-04-05 EP disclosed
US-20050026935-A1 Compounds XENTION DISCOVERY LTD. 2005-02-03 US disclosed
WO-2004111057-A1 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS XENTION DISCOVERY LIMITED (GB) 2004-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050026935-A1 Compounds KCNJ11, KCNJ1, KCNH1 LMNA 1126/4885MAPK1 667/4885TSHR 2845/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.